A controlled trial of oxypertine in tardive dyskinesia.

Abstract

A study was undertaken to investigate the effects of oxypertine in treating tardive dyskinesia. The design was double-blind, placebo-controlled, between-patient, in 28 patients from whom previous medication was withdrawn, with 14 patients in each group. Treatment was for 4 weeks. Although more oxypertine patients improved than placebo, i.e. 71.4 vs. 50%, the results did not reach statistically significant difference. A further study is planned to increase the overall number of patients in the study, and to lengthen treatment periods.

• Authors: H L Freeman, S D Soni, L Carpenter
• Journal: International pharmacopsychiatry (Int Pharmacopsychiatry) Vol. 15 Issue 5 Pg. 281-91 ( 1980) ISSN: 0020-8272 [Print] Switzerland
• PMID: 6114934 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antipsychotic Agents
• Indoles
• Piperazines
• Dopamine

Topics

• Adolescent
• Adult
• Aged
• Antipsychotic Agents (adverse effects)
• Clinical Trials as Topic
• Dopamine (metabolism)
• Double-Blind Method
• Dyskinesia, Drug-Induced (drug therapy)
• Female
• Humans
• Indoles (therapeutic use)
• Male
• Middle Aged
• Piperazines (therapeutic use)
• Time Factors